Atherosclerosis
Drug research and approvals for atherosclerosis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 395 studies of atherosclerosis are recruiting on ClinicalTrials.gov, and Health Canada has authorized 7 drug trials for it since 2013.
- Recruiting worldwide: 395
- Trials authorized in Canada: 7
- FDA orphan approvals: 0
- EU medicines: 0
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated…NCT07937254 · Phase 1 · Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd. · starts Oct 19, 2026
- Prospective Cohort Study of Patients Undergoing Coronary Angiography in Vorarlberg, AustriaNCT07932327 · Not reported · Vorarlberg Institute for Vascular Investigation and Treatment · starts Mar 24, 2022
- Edaravone Dexborneol for Blood-Brain Barrier Repair in Acute Anterior Circulation StrokeNCT07933692 · Phase 4 · Shandong Provincial Hospital · starts Oct 1, 2021
- Perioperative Limb Oxygenation Monitoring in Patients With CLTINCT07931768 · Not applicable · Belarusian State Medical University · starts Nov 2, 2026
- Integrated PET/MR Assessment of Brain Recovery After Recanalization of Non-Acute Atherosclerotic MCA OcclusionNCT07927569 · Not reported · Qianfoshan Hospital · starts Mar 21, 2024
- PET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite)NCT07916883 · Not reported · Washington University School of Medicine · starts Nov 18, 2026
- Coronary Myocardial Bridge and Coronary Plaques on MDCTNCT07916272 · Not reported · Sohag University · starts Oct 20, 2026
- Effect of Anifrolumab on Arterial Inflammation in Systemic Lupus Erythematosus StudyNCT07913919 · Not applicable · University of Cambridge · starts Nov 28, 2025
- Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis…NCT07881588 · Not applicable · Second Affiliated Hospital of Nanchang University · starts Apr 15, 2025
Approved 7
- RosuvastatinHMG-CoA reductase inhibitor
- Niacin
- AlirocumabSubtilisin/kexin type 9 inhibitor
- LovastatinHMG-CoA reductase inhibitor
- PravastatinHMG-CoA reductase inhibitor
- Bempedoic acidATP-citrate synthase inhibitor
- Inclisiran sodiumPCSK9 mRNA rnai inhibitor
Phase 3 12 of 47
- DarapladibLDL-associated phospholipase A2 inhibitor
- SimvastatinHMG-CoA reductase inhibitor
- AtorvastatinHMG-CoA reductase inhibitor
- ClopidogrelPurinergic receptor P2Y12 antagonist
- AspirinCyclooxygenase inhibitor
- EzetimibeNiemann-Pick C1-like protein 1 inhibitor
- Candesartan cilexetilType-1 angiotensin II receptor antagonist
- RamiprilAngiotensin-converting enzyme inhibitor
- RosiglitazonePeroxisome proliferator-activated receptor gamma agonist
- DiltiazemVoltage-gated L-type calcium channel blocker
- BenazeprilAngiotensin-converting enzyme inhibitor
- LisinoprilAngiotensin-converting enzyme inhibitor
Phase 2 12 of 13
- LosmapimodMAP kinase p38 alpha inhibitor
- RilapladibLDL-associated phospholipase A2 inhibitor
- Vitamin e
- AliskirenRenin inhibitor
- Salsalate
- ColchicineTubulin inhibitor
- AtreleutonArachidonate 5-lipoxygenase inhibitor
- PlozalizumabC-C chemokine receptor type 2 inhibitor
- Ascorbic acidSupplement
- PyridoxineSupplement
- CyanocobalaminSupplement
- PactimibeAcyl coenzyme A:cholesterol acyltransferase 1 inhibitor
Phase 1 or earlier 6
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- BMS-779788LXR-beta agonist
- BMS-962476
- Baxdrostat
- OlpasiranLPA mRNA rnai inhibitor
- Enlicitide
How its trials ended
1,497 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 284 whose ending is known, 40% met their primary endpoint, 18% missed it and 43% stopped early.
- Completed, result not reported65744%
- Ongoing29520%
- Status unknown26117%
- Met its primary endpoint1138%
- Stopped: other or unclear674%
- Missed its primary endpoint503%
- Stopped: enrollment or feasibility252%
- Stopped: sponsor or business decision121%
- Stopped: funding121%
- Stopped: lack of efficacy4<1%
- Stopped: safety1<1%
| Jun 10, 2026 | A randomized, multicenter, double-blind, parallel, placebo-controlled phase 2b clinical trial to evaluate the efficacy and safety of YN001 in adults with…YN001 (liposomal rosuvastatin) | Beijing Inno Medicine Co., Ltd. | Pending |
| Nov 21, 2025 | A phase IIa, multicenter, randomized, double-blind, placebo-controlled study of the efficacy, safety, pharmacodynamics, and pharmacokinetics of selnoflast in…Selnoflast (IZD-334, RO7486967) | Roche | Ongoing |
| Jun 24, 2024 | Platelet therapies for intracranial vascular atherostenosis (CAPTIVA)Rivaroxaban / Ticagrelor / Clopidogrel / Asa (acetylsalicylic acid) | University of Florida | Closed |
| May 14, 2024 | Nuance-icad: effect of genotype-guided oral P2Y12 inhibitor selection vs conventional clopidogrel therapy in symptomatic intracranial atherosclerotic disease:…Ticagrelor | Sunnybrook Research Institute | Ongoing |
| Jun 7, 2022 | A randomized, double-blind, placebo-controlled, phase 2b study of isis 678354 in patients with hypertriglyceridemia and atherosclerotic cardiovascular disease…Isis 678354 | Ionis Pharmaceuticals | Closed |
| Sep 17, 2020 | Metabolic and metagenomic effects of repopulation of the intestinal microbiome in patients with severe unexplained atherosclerosis.Fecal microbiota transplantation | St Josephs Healthcare | Pending |
| Aug 28, 2017 | Mineralocorticoid receptor antagonism clinical evaluation in atherosclerosisSpironolactone | University Hospitals Cleveland Medical Center | Ongoing |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA